IQVIA Holdings Valuation
Is IQV * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of IQV * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IQV * (MX$3886) is trading below our estimate of fair value (MX$4298.28)
Significantly Below Fair Value: IQV * is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IQV *?
Other financial metrics that can be useful for relative valuation.
What is IQV *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$41.79b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 3.6x |
Enterprise Value/EBITDA | 19.6x |
PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does IQV *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 44.2x | ||
A Agilent Technologies | 36.2x | 9.0% | US$45.0b |
LONN Lonza Group | 56.3x | 20.7% | CHF36.8b |
MTD Mettler-Toledo International | 41.2x | 8.3% | US$32.5b |
WST West Pharmaceutical Services | 42.8x | 10.8% | US$24.5b |
IQV * IQVIA Holdings | 30.3x | 12.9% | Mex$41.8b |
Price-To-Earnings vs Peers: IQV * is good value based on its Price-To-Earnings Ratio (30.3x) compared to the peer average (44.2x).
Price to Earnings Ratio vs Industry
How does IQV *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: IQV * is good value based on its Price-To-Earnings Ratio (30.3x) compared to the Global Life Sciences industry average (32.3x).
Price to Earnings Ratio vs Fair Ratio
What is IQV *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 30.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IQV *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$4,506.74 0% | 5.5% | Mex$4,897.83 | Mex$4,067.69 | n/a | 18 |
May ’25 | n/a | Mex$4,526.24 0% | 5.4% | Mex$4,930.83 | Mex$4,109.03 | n/a | 19 |
Apr ’25 | n/a | Mex$4,569.09 0% | 5.7% | Mex$5,008.14 | Mex$4,173.45 | n/a | 19 |
Mar ’25 | Mex$4,271.58 | Mex$4,678.66 +9.5% | 5.7% | Mex$5,128.23 | Mex$4,273.53 | n/a | 19 |
Feb ’25 | n/a | Mex$4,245.73 0% | 6.7% | Mex$4,929.52 | Mex$3,791.94 | n/a | 18 |
Jan ’25 | Mex$3,902.11 | Mex$4,059.67 +4.0% | 7.4% | Mex$4,635.33 | Mex$3,433.58 | n/a | 19 |
Dec ’24 | Mex$3,650.00 | Mex$3,947.07 +8.1% | 8.4% | Mex$4,452.30 | Mex$3,267.43 | n/a | 19 |
Nov ’24 | Mex$3,185.11 | Mex$4,324.64 +35.8% | 7.3% | Mex$4,720.26 | Mex$3,740.58 | n/a | 19 |
Oct ’24 | Mex$3,572.00 | Mex$4,426.68 +23.9% | 5.7% | Mex$4,933.01 | Mex$3,862.14 | n/a | 19 |
Sep ’24 | Mex$3,785.50 | Mex$4,312.27 +13.9% | 5.6% | Mex$4,791.42 | Mex$3,751.29 | n/a | 20 |
Aug ’24 | Mex$3,673.00 | Mex$4,254.78 +15.8% | 8.0% | Mex$4,805.47 | Mex$3,372.26 | n/a | 20 |
Jul ’24 | Mex$3,787.11 | Mex$4,225.09 +11.6% | 8.1% | Mex$4,882.22 | Mex$3,426.12 | n/a | 20 |
Jun ’24 | Mex$3,502.00 | Mex$4,329.38 +23.6% | 8.2% | Mex$5,023.10 | Mex$3,524.98 | n/a | 20 |
May ’24 | Mex$3,327.97 | Mex$4,409.67 +32.5% | 8.1% | Mex$5,109.65 | Mex$3,585.72 | n/a | 21 |
Apr ’24 | Mex$3,545.11 | Mex$4,712.91 +32.9% | 4.6% | Mex$5,194.52 | Mex$4,283.20 | n/a | 21 |
Mar ’24 | Mex$3,874.00 | Mex$4,786.49 +23.6% | 4.0% | Mex$5,237.19 | Mex$4,318.38 | Mex$4,271.58 | 19 |
Feb ’24 | Mex$4,243.25 | Mex$4,824.51 +13.7% | 5.1% | Mex$5,358.91 | Mex$4,324.74 | n/a | 19 |
Jan ’24 | n/a | Mex$5,035.76 0% | 5.4% | Mex$5,631.69 | Mex$4,544.87 | Mex$3,902.11 | 19 |
Dec ’23 | Mex$4,167.12 | Mex$4,985.42 +19.6% | 5.6% | Mex$5,570.72 | Mex$4,495.67 | Mex$3,650.00 | 18 |
Nov ’23 | Mex$4,150.19 | Mex$5,089.93 +22.6% | 5.8% | Mex$5,620.17 | Mex$4,535.58 | Mex$3,185.11 | 18 |
Oct ’23 | Mex$3,655.31 | Mex$5,351.81 +46.4% | 6.6% | Mex$5,966.10 | Mex$4,673.45 | Mex$3,572.00 | 18 |
Sep ’23 | Mex$4,362.11 | Mex$5,373.75 +23.2% | 6.0% | Mex$5,965.92 | Mex$4,673.30 | Mex$3,785.50 | 18 |
Aug ’23 | Mex$4,692.68 | Mex$5,447.24 +16.1% | 5.6% | Mex$5,957.59 | Mex$4,827.70 | Mex$3,673.00 | 19 |
Jul ’23 | Mex$4,279.03 | Mex$5,283.10 +23.5% | 6.6% | Mex$5,839.03 | Mex$4,731.63 | Mex$3,787.11 | 18 |
Jun ’23 | Mex$4,202.63 | Mex$5,281.75 +25.7% | 7.9% | Mex$6,164.97 | Mex$4,673.45 | Mex$3,502.00 | 17 |
May ’23 | Mex$4,377.98 | Mex$5,463.94 +24.8% | 7.6% | Mex$6,334.14 | Mex$4,801.68 | Mex$3,327.97 | 17 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.